Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?

Regeneron Pharmaceuticals, Inc. (REGN), is a biotechnology company headquartered in Tarrytown, New York, with a market cap of around $82.6 billion. The company specializes in discovering, developing, manufacturing, and commercializing transformative medicines across a broad range of serious diseases, including eye diseases, allergy and inflammation, cancer, cardiovascular, neurological, infectious, hematologic, and rare diseases.

Companies with a market cap of $10 billion or more are typically classified as “large-cap” stocks, and Regeneron Pharmaceuticals comfortably falls within this group. The biotechnology leader is widely recognized for its diverse portfolio of innovative medicines and its development of breakthrough therapies.

Fundamentals

See More
  • Market Capitalization, $K 82,638,152
  • Shares Outstanding, K 105,720
  • Annual Sales, $ 14,343 M
  • Annual Income, $ 4,505 M
  • EBIT $ 3,578 M
  • EBITDA $ 4,122 M
  • 60-Month Beta 0.40
  • Price/Sales 5.76
  • Price/Cash Flow 18.62
  • Price/Book 2.64

Options Overview Details

View History
  • Implied Volatility 37.31% (+0.97%)
  • Historical Volatility 25.49%
  • IV Percentile 50%
  • IV Rank 32.83%
  • IV High 60.01% on 04/08/25
  • IV Low 26.22% on 11/26/25
  • Expected Move (DTE 5) 13.06 (1.67%)
  • Put/Call Vol Ratio 0.85
  • Today's Volume 1,126
  • Volume Avg (30-Day) 1,683
  • Put/Call OI Ratio 0.67
  • Today's Open Interest 46,314
  • Open Int (30-Day) 46,129
  • Expected Range 768.61 to 794.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 5.96
  • Number of Estimates 6
  • High Estimate 8.00
  • Low Estimate 4.29
  • Prior Year 6.43
  • Growth Rate Est. (year over year) -7.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
731.51 +6.86%
on 02/02/26
815.00 -4.09%
on 02/17/26
+10.42 (+1.35%)
since 01/27/26
3-Month
691.86 +12.98%
on 12/09/25
821.11 -4.80%
on 01/09/26
-2.94 (-0.37%)
since 11/26/25
52-Week
476.49 +64.05%
on 06/05/25
821.11 -4.80%
on 01/09/26
+78.89 (+11.23%)
since 02/27/25

Most Recent Stories

More News
Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?

Although Regeneron Pharmaceuticals has lagged the Nasdaq over the past year, analysts remain highly bullish about its prospects.

$NASX : 22,668.21 (-0.92%)
REGN : 781.67 (+1.41%)
AMGN : 388.16 (+2.33%)
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment

If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is...

REGN : 781.67 (+1.41%)
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders

Key Takeaways: Regeneron will extend its title sponsorship of the Regeneron Science Talent Search (STS) for a second decade, continuing its partnership with Society for Science to support the United...

REGN : 781.67 (+1.41%)
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared...

REGN : 781.67 (+1.41%)
Is Wall Street Bullish or Bearish on Regeneron Pharmaceuticals Stock?

Regeneron Pharmaceuticals has outperformed the broader market over the past year, and analysts remain highly upbeat about the stock’s growth potential.

XLV : 160.20 (+1.77%)
$SPX : 6,878.88 (-0.43%)
REGN : 781.67 (+1.41%)
Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability  If approved,...

REGN : 781.67 (+1.41%)
1 Healthcare Stock Worth Your Attention and 2 Facing Challenges

1 Healthcare Stock Worth Your Attention and 2 Facing Challenges

ILMN : 134.46 (+5.54%)
MOH : 154.05 (+5.25%)
REGN : 781.67 (+1.41%)
Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:  REGN ) will webcast management participation as follows: TD Cowen 46th Annual Health Care Conference...

REGN : 781.67 (+1.41%)
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy

36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies ...

REGN : 781.67 (+1.41%)
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases

TARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual Angiogenesis...

REGN : 781.67 (+1.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 817.70
2nd Resistance Point 802.19
1st Resistance Point 791.93
Last Price 781.67
1st Support Level 766.16
2nd Support Level 750.65
3rd Support Level 740.39

See More

52-Week High 821.11
Last Price 781.67
Fibonacci 61.8% 689.46
Fibonacci 50% 648.80
Fibonacci 38.2% 608.13
52-Week Low 476.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar